Merck KGaA (MRK) PT Set at €96.00 by Deutsche Bank

Deutsche Bank set a €96.00 ($111.63) price target on Merck KGaA (FRA:MRK) in a research report report published on Thursday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.

Several other research analysts have also weighed in on the company. Nord/LB set a €80.00 ($93.02) target price on Merck KGaA and gave the stock a sell rating in a research report on Thursday, January 24th. HSBC set a €96.00 ($111.63) target price on Merck KGaA and gave the stock a neutral rating in a research report on Monday, March 11th. Sanford C. Bernstein set a €105.00 ($122.09) target price on Merck KGaA and gave the stock a buy rating in a research report on Thursday, March 7th. Goldman Sachs Group set a €95.00 ($110.47) target price on Merck KGaA and gave the stock a neutral rating in a research report on Tuesday, February 12th. Finally, JPMorgan Chase & Co. set a €100.00 ($116.28) target price on Merck KGaA and gave the stock a neutral rating in a research report on Monday, February 18th. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of €101.35 ($117.85).

MRK stock traded down €0.04 ($0.05) during mid-day trading on Thursday, hitting €91.62 ($106.53). The stock had a trading volume of 497,029 shares. Merck KGaA has a 1-year low of €76.60 ($89.07) and a 1-year high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Featured Article: How are institutional investors different from individual investors?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.